Dr. Christian Rolfo

About Dr. Christian Rolfo

Dr. Christian Rolfo specializes in treatment for thoracic malignancies such as pleural mesothelioma and lung cancer, translational oncology and new drug development. He applies his extensive experience in clinical research and clinical trial management from his time at leading global care centers to his work today at The James Comprehensive Cancer Center at OSU, located in Columbus, Ohio. His extensive published research highlights his thought leadership in thoracic oncology. 

He was appointed president of the International Society of Liquid Biopsy, a nonprofit organization that works toward erasing restrictions on liquid biopsy implementation in routine clinical practice. Dr. Rolfo is also part of the Educational Committee of the International Association for the Study of Lung Cancer and on the Membership Committee of the European Society of Medical Oncology.

Close Button

Full Name

Diagnosis Please Select Mesothelioma Asbestosis Lung Cancer No Diagnosis Other Unknown

Zip Code

Email

Phone Number

Preferred Method of Contact Please Select Call Text

Message

Full Name

By clicking Get Connected Now, you agree to be contacted by Asbestos.com’s Patient Advocates with health-related information and services via call, text/SMS using an automated dialing platform and/or email at the telephone number and/or email you provided. Std. msg./data rates apply and your consent to such contact/marketing is not required for purchase of services. You also agree to our Privacy Policy and Terms of Service, including the agreement to arbitrate disputes.

Get Connected Now

Medical Education & Expertise

• The James Comprehensive Cancer Center, Ohio State University
• Mount Sinai School of Medicine, Center for Thoracic Oncology at The Tisch Cancer Institute, (Professor of Medicine and Associate Director for Clinical Research)
• University of Maryland Greenebaum Comprehensive Cancer Center
• Antwerp University Hospital in Belgium (Director of the Clinical Trials Management Program)
• University of Palermo, Italy (PhD)
• Polytechnic University of Valencia, Spain (MBA)
• University of Milan (Internship)
• University of Milan (Fellowship)
• National Cancer Institute, Milan, Italy (Residency)
• University of Cordoba School of Medicine (M.D.)

Associations, Awards & Recognition

• Editorial Board Member, Belgian Journal of Medical Oncology
• Educational Committee Member, International Association for the Study of Lung Cancer 
• Former Membership Committee Member, International Association for the Study of Lung Cancer
• President, International Society of Liquid Biopsy
• Section Editor Investigational Drug Research, Critical Reviews in Oncology Hematology

Why Choose Dr. Christian Rolfo for Pleural Mesothelioma?

Dr. Rolfo pioneers innovative treatments, including combining immunotherapy with proton beam therapy, and advances liquid biopsy techniques for better diagnosis and personalized care. As director at The James Comprehensive Cancer Center, he leads clinical trials that give pleural mesothelioma patients access to cutting-edge therapies.

Dr. Rolfo’s focus on integrating research with compassionate care ensures pleural mesothelioma patients receive the most advanced and individualized treatment options. Dr. Rolfo notes, “We have immunotherapy treatment today that can be specific to tumors and attack cancer cells. We are diagnosing genetic alterations for more targeted therapy today. The results have been encouraging.”

Publications of Dr. Rolfo

Rolfo, C. et al. (2025, October 17). Artificial intelligence-based pharmacological approach in non-small cell lung cancer in the precision medicine era. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41138717/

Rolfo, C. et al. (2025, August 21). BLOODPAC’s collaborations with European Union liquid biopsy initiatives. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41018162/

Rolfo, C. et al. (2025, May 24). International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40521567/

Rolfo, C. et al. (2025, March 28). CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40154411/

Rolfo, C. et al. (2024, October). New diagnostic and nonsurgical local treatment modalities for early stage lung cancer. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39236577/